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Leptin is a vertebrate-specific, adipocyte-derived 
hormone regulating, among other functions, 
appetite and energy expenditure after its sig-
naling  in  the  brain  (Flier  and  Elmquist,  1997; 
Friedman  and  Halaas,  1998;  Spiegelman  and 
Flier, 2001). Numerous studies in the last 16 yr 
aimed at drawing a precise map of the circuitry 
used by leptin signaling in the brain to fulfill its 
functions (Elmquist et al., 1997; Takeda et al., 
2002;  Balthasar  et  al.,  2004,  2005;  Gao  and 
Horvath, 2008; Scott et al., 2009; Yadav et al., 
2009; Grill, 2010). After the lead provided by 
chemical lesion experiments and expression 
studies of the leptin receptor, the majority of 
these  studies  assumed  that  leptin  signals  in   
hypothalamic neurons to regulate appetite and 
energy expenditure (Elmquist, 2000; Elmquist 
et  al.,  2005;  Coll  et  al.,  2007).  Surprisingly, 
however, cell-specific deletion experiments of 
the  leptin  receptor  in  various  hypothalamic 
neurons have failed to affect appetite or en-
ergy expenditure in mice fed a normal chow,   
which is something leptin deficiency achieves 
(Balthasar  et  al.,  2004;  Dhillon  et  al.,  2006). 
These data raised the hypothesis that leptin may 
act elsewhere in the brain to affect appetite. 
Consistent with this hypothesis, a combination 
of cellular, electrophysiological, and genetic ex-
periments revealed that leptin inhibits appetite 
in mice by decreasing the synthesis in and   
release  from  brainstem  neurons  of  serotonin, 
which, after its binding to the Htr1a and Htr2b 
receptors, favors appetite (Srinivasan et al., 2008; 
Yadav et al., 2009). Thus, providing an explana-
tion for the lack of effect on appetite of the 
cell-specific deletion of the leptin receptor in 
hypothalamic neurons, these experiments indi-
cated that leptin acts outside the hypothalamus, 
in the brainstem, as an inhibitor of the synthesis 
of an activator of appetite, serotonin.
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Recent evidence indicates that leptin regulates appetite and energy expenditure, at least  
in part by inhibiting serotonin synthesis and release from brainstem neurons. To demonstrate 
that this pathway works postnatally, we used a conditional, brainstem-specific mouse 
CreERT2 driver to show that leptin signals in brainstem neurons after birth to decrease 
appetite by inhibiting serotonin synthesis. Cell-specific gene deletion experiments and 
intracerebroventricular leptin infusions reveal that serotonin signals in arcuate nuclei of 
the hypothalamus through the Htr1a receptor to favor food intake and that this serotonin 
function requires the expression of Creb, which regulates the expression of several genes 
affecting appetite. Accordingly, a specific antagonist of the Htr1a receptor decreases food 
intake in leptin-deficient but not in Htr1a/ mice. Collectively, these results establish that 
leptin inhibition of serotonin is necessary to inhibit appetite postnatally and provide a 
proof of principle that selective inhibition of this pathway may be a viable option to treat 
appetite disorders.
© 2011 Yadav et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Tph2-CreERT2 transgene should be explained by the lack of 
expression of this gene in serotonergic neurons.
Postnatal deletion of the leptin receptor in serotonergic 
neurons affects appetite and energy expenditure
We next used this Tph2-CreERT2 transgenic mouse to delete 
Obrb in serotonergic neurons of the brainstem after birth. For 
that purpose, we performed daily tamoxifen (1 mg/20 g BW) 
injections over 5 d in 6-wk-old Tph2-CreERT2 and Tph2-
CreERT2; Obrbf/f. Tph2-CreERT2; Obrbf/f mice gained signifi-
cantly more weight than control littermates (Fig. 1 B). 6 wk 
after the end of this tamoxifen treatment, appetite (+32%), 
BW (+33%), and fat pad weight (+35%) were significantly 
increased, whereas energy expenditure was significantly de-
creased in Tph2-CreERT2; Obrbf/f mice compared with WT or 
Tph2-CreERT2 mice that were heterozygous for Tph2 inacti-
vation  and  therefore  mildly  anorexic  (Fig.  1,  C–H; Yadav   
et al., 2009). To demonstrate molecularly that the deletion of   
Obrb selectively in Tph2-expressing neurons after birth could 
affect appetite, we measured expression of genes such as pro-
opiomelanocortin- (Pomc-1) and melanocortin receptor 4 (Mc4r) 
that contribute to the regulation of appetite (Huszar et al., 1997; 
Cowley et al., 2001; Balthasar et al., 2005; Coll et al., 2007) 
and whose expression in the hypothalamus is decreased by the 
absence of leptin signaling in serotonergic neurons (Coll   
et al., 2007;  Yadav et al., 2009). Consistent with their decreased 
appetite, expression of Pomc-1 and Mc4r was increased in hy-
pothalami of Tph2-Cre; Obrbf/f mice (Fig. 1 I). Collectively, 
these results indicate that leptin signaling in serotonergic neu-
rons of the brainstem is necessary to regulate appetite and en-
ergy expenditure in adult mice.
Ablation of Htr1a and Htr2b in Pomc-expressing neurons  
of the arcuate nuclei decreases appetite
Next we asked where in the brain serotonin signals through 
the Htr1a receptor to regulate appetite. Because neurons of 
the arcuate nuclei of the hypothalamus are implicated in the 
regulation of appetite and energy expenditure (Cowley et al., 
2001; Pinto et al., 2004; Balthasar et al., 2005; Coll et al., 
2007), we asked whether it is through its expression in these 
neurons that the Htr1a receptor regulates appetite.
To address this question, we crossed mice harboring a 
floxed allele of Htr1a with Pomc-Cre transgenic mice that   
express Cre in Pomc-expressing neurons of the arcuate nuclei 
(Balthasar et al., 2004). In situ hybridization analysis verified 
that Htr1a expression in arcuate neurons was completely ab-
lated in Htr1aPomc
/ mice (Fig. 2 A). We should point out that 
Pomc1  is  also  expressed  in  the  pituitary  gland  and  caudal 
brainstem (Salbert et al., 1992). 3-mo-old Htr1aPomc
/ mice 
demonstrated a significant reduction in food intake (19%) 
that led to a significant decrease in BW (20%; Fig. 2, B and 
C). As Htr2b, another serotonin receptor affecting appetite, is 
also expressed in Pomc-expressing neurons (Yadav et al., 2009), 
we generated mutant mice lacking both Htr1a and Htr2b in 
Pomc-expressing  neurons  (Htr1a;2bPomc
/  mice).  In  these 
double mutant mice, appetite was significantly lower (36%) 
The prominent role ascribed to brain serotonin in this 
model of leptin regulation of appetite raises several questions. 
First, because it is based, in part, on cell-specific gene deletion 
of the leptin receptor, it needs to be verified through the use 
of a Cre driver whose activity is even more exquisitely lim-
ited to serotonergic neurons of the brainstem. Second (and 
this is a more important issue), one needs to demonstrate that 
this regulatory loop takes place during adult life. Third, if in-
deed leptin inhibits appetite by preventing synthesis and re-
lease of serotonin, one needs to identify the neurons on which 
serotonin acts and to decipher, at least in part, the transcrip-
tional events elicited by serotonin in these neurons. Lastly, an 
implication of this model is that pharmacologically inhibit-
ing serotonin signaling should affect appetite in mice lacking 
leptin. Testing this latter issue is critical not only to formally 
demonstrate that leptin inhibits appetite by inhibiting sero-
tonin synthesis but also because it could pave the way for 
novel therapeutic avenues to treat obesity.
This study addressed these four issues. Specifically, we pro-
vide additional evidence, based on the use of a tamoxifen- 
inducible CreERT2 driver whose expression is restricted to 
Tph2-expressing neurons, that leptin signaling in brainstem 
neurons does affect appetite postnatally. We show that it is 
through its expression in arcuate neurons of the hypothala-
mus that the Htr1a receptor favors appetite and that it does so 
by recruiting the transcription factor CREB. Lastly, using a 
pharmacological approach, we demonstrate that a specific   
antagonist of Htr1a decreases food intake in leptin-deficient 
mice and weakens their obesity.
RESULTS
Characterization of an inducible Tph2-CreERT2 mouse model
To establish that leptin signals in brainstem neurons to control 
appetite in mice fed a normal chow and that this pathway is 
operating after birth, we used mice in which the conditional 
CreERT2 was inserted at the ATG in a bacterial artificial chro-
mosome clone containing the entire mouse Tph2, the gene 
encoding the initial enzyme in brainstem serotonin synthesis. 
In this construct, expression of the Cre recombinase should   
be under the control of Tph2-regulating elements and there-
fore expressed in serotonergic neurons of the brainstem only 
(Fig. 1 A). To ascertain the cell-specific activity of the reg-
ulatory elements contained in this bacterial artificial chro-
mosome, we crossed Tph2-CreERT2 transgenic mice with 
Rosa26R  mice  (Soriano  1999).  In  this  mouse  model,  the   
-Galactosidase reporter gene, containing a floxed transcrip-
tional blocker cassette inserted between the transcription start 
site and the ATG, is placed downstream of the Rosa26 pro-
moter. Thus, -galactosidase can only be expressed after Cre-
mediated  deletion  of  the  transcriptional  blocking  cassette. 
After treatment of 6-wk-old mice with tamoxifen (1 mg/20 g 
body weight [BW] successively over 5 d), -galactosidase 
staining showed that this construct drives gene expression in 
serotonergic neurons of the brainstem (stained in blue) but 
not in hypothalamic or any other neurons (Fig. S1). Thus, 
phenotypes developed by mutant mice generated using this JEM VOL. 208, January 17, 2011 
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Figure 1.  Leptin signaling in serotonergic neurons of the raphe nuclei. (A) Schematic drawing of the Tph2-CreERT2 construct. CreERT2 cassette was 
placed under the control of Tph2 regulatory elements by insertion at the ATG of the Tph2 locus. (B) Measurement of daily weight gain (grams) over 3 wk 
in WT, Tph2-CreERT2, and Tph2-CreERT2 Obrb mice (n = 3 for each group). The measurement started 7 d after the first tamoxifen injection. (C–H) BW 
(grams; n = 3 for each group; C), fat pad weight (fat pad weight/BW; n = 3 for each group; D), food intake (grams/day; n = 3 for each group; E), and (F–H) 
energy expenditure analysis in WT, Tph2-CreERT2, and Tph2-CreERT2 Obrb mice 2 mo after tamoxifen injection (n = 3 for each group). Volume of oxygen 
consumption VO2 (milliliters/kilogram/hour; F), heat production (kilocalories/hour/BW; G), and locomotor activity (XTOT; H) are shown. (I) Quantitative PCR 
analysis of Mc4r, Pomc-1, Cart (Cocaine and amphetamine regulated transcript), Mch (Melanin-concentrating hormone receptor 1), and Hyp (hypocretin) 
in WT (n = 4), Tph2-CreERT2 (n = 3), and Tph2-CreERT2Obrb (n = 4) hypothalami 2 mo after tamoxifen injection. Data shown are representative of two 
independent experiments. For all experiments: *, P < 0.05 (Student’s t test). Error bars represent SEM.44 Leptin-dependent serotonin control of appetite | Yadav et al.
Figure 2.  Brain-derived serotonin regulates appetite through the Htr1a and Htr2b receptors expressed in arcuate neurons. (A) Expression 
analysis of Htr1a in WT and Htr1aPomc
/ hypothalamus by in situ hybridization compared with Pomc-1 in arcuate (Arc) nuclei (outlined by dashed line; 
experiment was performed using three different brains for each group). Bars, 500 µm. (B) Measurement of food intake (grams) over 12 and 24 h in WT, 
Htr1aPomc
+/, and Htr1aPomc
/ mice (n = 6 for each group). (C) BW (grams) analysis in WT, Htr1aPomc
+/, and Htr1aPomc
/ mice at 3 and 6 mo of age  
(n = 6 for each group). (D) Measurement of food intake (grams) over 12 and 24 h in WT (n = 6) and Htr1a;2bPomc
/ (n = 4) mice. (E) Quantitative PCR 
analysis of Mc4r, Pomc-1, Cart (Cocaine and amphetamine regulated transcript), Mch (Melanin-concentrating hormone receptor 1), and Hyp (hypocretin) 
in WT (n = 8), Htr1aPomc
/ (n = 4), and Htr1a;2bPomc
/ (n = 4) hypothalami. Data shown are representative of three independent experiments.  
(F and G) Measurement of food intake (grams) over 12 and 24 h in WT (F) and quantitative PCR analysis of gene controlling appetite in WT mice infused 
with vehicle (n = 6) and WT (n = 6) and Htr1a;2bPomc
/ (n = 6) mice infused by leptin (4 ng/h) for 7 d (G). Data shown are representative of two independent 
experiments. For all experiments: *, P < 0.05; **, P < 0.01 (Student’s t test). Error bars represent SEM.JEM VOL. 208, January 17, 2011 
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than a mere additive effect of the two mutations would have 
predicted (Fig. 2 D). Moreover, we observed an up-regulation 
of  Pomc-1  and  Mc4r  expression  in  Htr1aPomc
/  and 
Htr1a;2bPomc
/  mice  hypothalami,  providing  a  molecular 
mechanism whereby the deletion of Htr1a and of Htr1a and 
Htr2b  from  Pomc-expressing  neurons  could  affect  appetite 
(Fig. 2 E). Collectively, these results establish that serotonin 
signals in Pomc-expressing neurons through Htr1a and Htr2b 
to favor appetite.
Leptin anorexigenic function requires serotonin signaling  
in arcuate neurons of the hypothalamus
Is serotonin signaling in neurons of the arcuate nuclei neces-
sary for leptin regulation of appetite? If this is the case, leptin 
should not affect appetite in mice lacking serotonin signaling 
in hypothalamic neurons. To address this question, we infused 
leptin (4 ng/h) in the third ventricle of  WT and Htr1a;2bPomc
/ 
for 10 d and then measured food intake and expression of 
genes affecting appetite. We did not observe any difference   
in  Mc4r  and  Pomc-1  gene  expression  and  food  intake  in 
Htr1a;2bPomc
/ hypothalami after leptin infusion (+32%) 
compared with untreated Htr1a;2bPomc
/ (+36%; Fig. 2,   
F and G). These data confirmed that leptin acts as an inhibitor 
of serotonin signaling in arcuate neurons of the hypothalamus 
to inhibit food intake.
Creb expression in arcuate neurons of the hypothalamus  
is necessary for serotonin regulation of appetite
Htr1a is a Gs protein–coupled receptor signaling through the 
cAMP-PKA–dependent pathway. The main transcription fac-
tor downstream of this pathway is CREB, which mediates 
other homeostatic functions of serotonin (Yadav et al., 2008; 
Oury et al., 2010). Thus, we asked whether CREB, through 
its expression in neurons of the arcuate nuclei, was also in-
volved in serotonin’s regulation of appetite.
To address this question, we first used hypothalamic ex-
plant cultures. Immunofluorescence of phosphorylated CREB 
(p-CREB) showed that serotonin treatment of these explants 
increased CREB phosphorylation in arcuate neurons (Fig. 3 A). 
To establish in vivo that CREB mediates serotonin regulation 
of appetite through its expression in arcuate neurons, we   
generated mice lacking Creb in Pomc-expressing neurons   
(CrebPomc
/ mice). CrebPomc
/ mice showed a significant re-
duction in food intake (31%), BW (20%), and normal en-
ergy expenditure (Fig. 3, B and C; and Fig. S2). Furthermore, 
expression of genes inhibiting food intake such as Mc4r and 
Pomc-1 was significantly increased in CrebPomc
/ hypothalami 
(Fig. 3 D). These data indicate that CREB signaling in the 
Pomc-expressing  neurons  regulates  food  intake  in  part  by   
favoring Mc4r and Pomc-1 expression.
To establish that this function of CREB occurs after sero-
tonin signaling in arcuate neurons, we generated compound 
heterozygous mice lacking one copy of Creb and one copy of 
Htr1a in Pomc-expressing neurons of the arcuate nuclei. These 
mice also showed decrease of appetite (23% after 24 h), in-
crease of Mc4r and Pomc-1 expression, and normal energy   
expenditure (Fig. 3, E and F; and Fig. S3), thereby providing 
strong support to the hypothesis that CREB is a transcrip-
tional effector of serotonin’s regulation of appetite.
CREB regulates expression of genes involved in the control 
of appetite in arcuate neurons
Next we asked whether CREB regulates other genes besides 
Mc4r and Pomc-1 that could account for the orexigenic function 
of serotonin. To that end, we isolated hypothalami of WT and 
CrebPomc
/ mice and performed a microarray experiment.
Among large numbers of genes whose expression was   
altered by the absence of Creb in Pomc-expressing neurons   
(Fig. 4, A and B), we focused on two genes whose expression 
was up-regulated in CrebPomc
/ hypothalami. Those are neuro-
peptide VF (Npvf), which has been shown to induce satiety 
(Cline et al., 2008; Cline and Sliwa, 2009), and aspartoacyclase 
(aminocyclase  3  [Acy3];  Gordon,  2001; Velinov  et  al.,  2008; 
Caliebe et al., 2010), which encodes an enzyme that is inacti-
vated in patients with aspartoacylase deficiency that have in-
creased appetite. One and four canonical binding sites for 
CREB are present in the Acy3 and Npvf promoter, respec-
tively (Fig. S4). We verified by real-time PCR that expression 
of these two genes was increased in CrebPomc
/ hypothalami 
(Fig. 4, C and D). Adding further evidence that these genes 
are downstream effectors of the serotonin orexigenic func-
tion, we also observed an increase of their expression in hy-
pothalami  of  Tph2/,  Htr1aPomc
/;  Htr1a;2bPomc
/,  and 
CrebPomc
/ mice (Fig. 4, C and D). Moreover, the fact that the 
expression of Npvf and Acy3 was strongly decreased in ob/ob 
hypothalami, whereas acute leptin intracerebroventricular in-
jection in these mice increased their expression, demonstrates 
that Npvf and Acy3 are downstream of leptin signaling in the 
brain. Collectively, these data establish that under the control 
of leptin and serotonin, CREB transcriptional activity in ar-
cuate neurons affects the expression of genes that have been 
shown to modulate appetite.
Pharmacological targeting of Htr1a receptor decreases 
appetite in mice
If serotonin favors appetite through the Htr1a receptor, inhi-
bition of serotonin signaling through this receptor should   
decrease appetite in WT mice. Moreover, if leptin inhibits   
appetite by decreasing serotonin synthesis and release, this 
compound should decrease appetite in ob/ob mice that are 
leptin deficient. This last point is needed to validate the no-
tion that leptin decreases appetite by inhibiting serotonin sig-
naling in the hypothalamus and to show that, if achievable, 
inhibition of serotonin signaling could be an alternative strat-
egy in the treatment of obesity.
To address these questions, we used a small molecule   
antagonizing serotonin signaling through the Htr1a receptor 
only because we have been unable so far to obtain a small 
molecule antagonizing signaling through Htr2b. This mole-
cule (LY426965) has high affinity for the Htr1a receptor   
(Ki = 4.66 nM) and 20-fold or greater selectivity over other 
serotonin and nonserotonin receptor subtypes (Fig. 5 A;   46 Leptin-dependent serotonin control of appetite | Yadav et al.
Figure 3.  Creb expression in arcuate neurons is necessary for brain-derived serotonin regulation of appetite. (A) Analysis of CREB phosphory-
lation by immunofluorescence using p-CREB (S133) antibody. Immunofluorescence was performed on coronal sections of WT hypothalamic explants pre-
viously treated with vehicle or 50 µM serotonin for 30 min (n = 5 each). Brightfield images of hypothalamic sections (top) are shown; the black boxes 
delimit the frame for the immunofluorescence analysis shown below. Arcuate nuclei (Arc) and the third ventricle (3V) are outlined by dashed and solid 
lines, respectively. Data shown are representative of three independent experiments. VMH, ventromedial hypothalamus nucleus. Bars, 500 µm.  
(B and C) Measurement of food intake (grams) for a period of 12 and 24 h (B) and BW (grams) in 3- and 6-mo-old WT, CrebPomc
+/, and CrebPomc
/ mice 
(n = 6 for each group; C). Figures show combined data from two independent experiments. (D) Quantitative PCR analysis of Mc4r, Pomc-1, Cart (Cocaine 
and amphetamine regulated transcript), Mhc (Melanin-concentrating hormone receptor 1), and Hyp (hypocretin) in WT and CrebPomc
/ hypothalami  
(n = 6 for each group). Data shown are representative of two independent experiments. (E) Measurement of food intake (grams) over a period of 12 and 
24 h in WT (n = 4) and Htr1a;CrebPomc
+/ (n = 5) mice. (F) Quantitative PCR analysis of Mc4r, Pomc-1, Cart (Cocaine and amphetamine regulated tran-
script), Mhc (Melanin-concentrating hormone receptor 1), and Hyp (hypocretin) in WT (n = 4) and Htr1a;CrebPomc
/ (n = 5) hypothalami. Data shown are 
representative of two independent experiments. For all experiments: *, P < 0.05 (Student’s t test). Error bars represent SEM.JEM VOL. 208, January 17, 2011 
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Rasmussen et al., 2000). That appetite and 
Mc4r and Pomc-1 expression were not de-
creased in Htr1aPomc
/ mice treated with 
LY426965 strongly suggests that this com-
pound acts as a specific inhibitor of Htr1a 
signaling (Fig. S5).
To evaluate LY426965 efficacy in inhib-
iting  signaling  through  Htr1a  receptors   
in the regulation of appetite, we fed 12-wk-
old C57BL/6J mice with either vehicle   
or LY426965 at doses ranging from 1 to   
20  mg/kg  BW  and  observed  a  dose- 
dependent decrease in appetite (Fig. 5 B). 
This decrease in food intake reached 77%   
of the control values when using 20 mg/kg 
of the compound (Fig. 5 B). We verified 
that LY426965 could reach the hypothal-
amus  by  performing  mass  spectrometric 
analysis of mice hypothalami after i.p. ad-
ministration of the compound. We could 
detect, in treated mice, LY426865 in hypo-
thalamic tissue at a concentration of 5 pg/mg 
when exposed to a plasma concentration of 
29.2 ng/ml (Fig. 5 C).
To demonstrate that LY426865 can act on 
arcuate  neurons  of  the  hypothalamus,  we 
treated hypothalamic explants obtained from 
WT  mice  with  either  vehicle  or  50  µM 
LY426865 in the presence or absence of   
50 µM serotonin for 30 min. Immunofluores-
cence showed an increase of phosphorylation 
Figure 4.  Microarray experiment comparing 
the expression of genes in hypothalami of WT 
mice and of mice lacking Creb only in arcuate 
neurons. (A and B) Heat map of the microarray 
analysis of three WT hypothalami versus hypothal-
ami of four mice lacking Creb only in arcuate neu-
rons (CrebPomc
/ mice). Genes significantly  
(P < 0.05) up (A)- or down-regulated (B) in the  
hypothalamus of CrebPomc
/ mice compared with WT 
littermates are shown. These genes are ordered by 
fold change from maximum to the threshold of 1.20. 
The genes down- or up-regulated are listed in the 
last column. (C) Quantitative PCR analysis of Acy3 
and Npvf expression in hypothalami of WT (n = 8), 
Htr1a Pomc
/ (n = 6), Htr1a;2bPomc
/ (n = 6),  
CrebPomc
/ (n = 6), and Tph2/ (n = 5) mice at  
12 wk of age. Data shown are representative of three 
independent experiments. (D) Quantitative PCR analy-
sis of Acy3 and Npvf expression in the hypothalami of 
WT and ob/ob mice after acute intracerebroventricu-
lar (ICV) injection with vehicle or 2 µg leptin (WT,  
n = 4; ob/ob, n = 6; WT + leptin ICV, n = 4; and  
ob/ob + leptin ICV, n = 4). Figure shows combined data 
from two independent experiments. For all experi-
ments: *, P < 0.05; **, P < 0.01 (Student’s t test). 
Error bars represent SEM.48 Leptin-dependent serotonin control of appetite | Yadav et al.
Figure 5.  Pharmacological targeting of Htr1a receptors in mice. (A) Organic structure of the Htr1a antagonist LY426965. (B) Measurement of food 
intake (grams) over a period of 12, 24, and 36 h after single i.p. injection of 5, 10, or 20 mg/kg BW of vehicle or LY426965 compound in 12-wk-old WT 
mice (n = 6 for each group). Figure shows combined data from two independent experiments. (C) Measurement by mass spectrometry of LY426965 com-
pound concentration in plasma (nanograms/milliliter) and hypothalamus (picograms/milligrams of tissue) of untreated and treated mice (n = 4 for each 
group). (D) Analysis of CREB phosphorylation by immunofluorescence using p-CREB (S133) antibody. Immunofluorescence was performed on coronal 
sections of WT hypothalamic explants previously treated with LY426965 compound, 50 µM serotonin, or LY426965 compound + 50 µM serotonin for 30 min. 
Brightfield images of hypothalamic sections (top) are shown; the black boxes delimit the frame for the immunofluorescence analysis shown below.  JEM VOL. 208, January 17, 2011 
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Tph2 is specifically expressed in serotonergic brainstem neu-
rons of the raphe nuclei. To drive Cre expression, we used here 
the regulatory elements of the Tph2 gene that encode the 
initial enzyme in the biosynthesis of serotonin in the brain-
stem. Thus, by definition, Cre should be expressed in seroto-
nergic neurons of the brainstem, although Tph2 has been 
shown to be expressed in other parts of the brain (Walther 
and Bader, 2003; Patel et al., 2004). We note that this Tph2-
CreERT2 driver mouse does not express Cre at a detectable 
level in any cell type other than brainstem neurons. That the 
use of this Cre driver to delete Obrb caused a severe hyper-
phagia phenotype provides more rigorous evidence support-
ing the notion that leptin signals in brainstem neurons to 
regulate appetite and energy expenditure. We remain aware 
that these results do not rule out the possibility that leptin 
may signal in additional neurons to inhibit appetite in mice 
fed a normal chow. Further experiments are required to iden-
tify such a neuronal population.
A second question generated by our previous results was 
to determine whether leptin uses this serotonin-dependent 
pathway during development only or also after birth (Yadav 
et al., 2009). To address this question, we were fortunate that 
the activity of the Tph2-CreERT2 driver we used here is in-
ducible by tamoxifen. This allowed us to show that leptin uses 
this pathway in mice that are at least 6 wk old, thus ruling out 
that it is only active during embryonic or perinatal develop-
ment. Together, these two sets of experiments, because of the 
exquisite specificity of expression of Cre and its postnatal ac-
tivation, support the notion that leptin signals in brainstem 
neurons to regulate appetite and energy expenditure.
If we now look at how serotonin itself favors appetite, we 
first established that it occurs in arcuate neurons and that 
CREB is one important transcriptional mediator of this func-
tion, although we cannot rule out that others exists. A micro-
array analysis identified at least two genes besides Mc4r and 
Pomc-1: Npvf and Acy3, whose expression is up-regulated in 
absence of CREB or serotonin signaling or by leptin acute 
injection and is down-regulated in the absence of leptin sig-
naling. Neuropeptide VF was recently described as a neuro-
peptide that induces hypothalamus associated-satiety in chicks 
(Cline et al., 2008; Cline and Sliwa, 2009), and this study 
strongly suggests for the first time that Npvf can also regulate 
appetite in mice. The second gene, Acy3, encodes an enzyme, 
aspartoacyclase, that is mutated in patients with an autosomal 
of CREB in arcuate neurons of the hypothalamus after treatment 
with serotonin, whereas CREB phosphorylation did not change 
when LY426865 alone was added to the medium (Fig. 5 D).
To determine whether LY426965 could decrease appetite 
in ob/ob mice, we administered 4-wk-old ob/ob mice with a 
single dose of LY426965 (0.4 mg/20 g BW) and measured 
food intake 12, 24, and 36 h later. Food intake in LY426965-
treated  animals  was  20–25%  lower  than  in  vehicle-treated 
mice at all time points analyzed, demonstrating that inhibition 
of signaling through Htr1a in ob/ob mice can reduce appetite 
(Fig. 5 E). That this compound did not fully rescue the appe-
tite phenotype caused by the absence of leptin is consistent 
with the notion that serotonin also decreases appetite by sig-
naling through Htr2b receptor. Given the success of this initial 
experiment, we then asked whether LY426965 could rescue, 
even partially, the hyperphagia of ob/ob mice if administered 
chronically. For that purpose, 4-wk-old ob/ob mice were ad-
ministered daily with a 20-mg/kg BW dose of LY426965 
for 4 wk. LY426965-mediated suppression of Htr1a receptor 
signaling significantly decreased the obesity phenotype of ob/ob 
mice (27%), whereas energy expenditure was not changed 
(Fig. 5, G–L). This result is consistent with the notion that one 
mechanism whereby leptin inhibits appetite is by decreasing 
serotonin synthesis and release from brainstem neurons and 
signaling trough the Htr1a receptor (Yadav et al., 2009).
DISCUSSION
The idea that leptin may not act directly in the hypothalamus 
to regulate appetite and energy metabolism was surprising.   
As a result, this finding needed to be verified and, if possible, 
its therapeutic potential explored. In all experiments, our pur-
pose was to study WT or mutant mice fed a normal chow. 
Our rationale for this choice was based on the fact that leptin 
anorexigenic function was discovered in mice fed this diet.
A first question, which is inherent to every cell-specific 
deletion experiment, is to rule out, as much as possible, that 
the effect observed is not caused by a spurious gene deletion 
in a cell type other than the one under study. To address this 
concern as thoroughly as possible, we used here a different 
Cre driver than the one we used initially (Yadav et al., 2009). 
Two tryptophan hydroxylase isoforms, Tph1 and Tph2, act as 
rate-limiting enzymes in serotonin synthesis. The expression 
of the two isoforms is mutually exclusive; Tph1 is abundantly 
expressed in the pineal gland and enterochromaffin cells, and 
Arcuate nuclei (Arc) and the third ventricle (3V) are outlined by dashed and solid lines, respectively (data shown are representative of four independent 
experiments). VMH, ventromedial hypothalamus nucleus. Bars, 500 µm. (E) Measurement of food intake (grams) over a period of 12, 24, and 36 h after 
single i.p. injection of 20 mg/kg BW of vehicle or LY426965 compound in 12-wk-old ob/ob mice (ob/ob + vehicle, n = 6; ob/ob + LY426965, n = 6).  
Data shown are representative of two independent experiments. (F) Daily weight gain (grams) after daily i.p. injection of vehicle or LY426965 compound 
(20 mg/kg/d). Measurement started 7 d after the first i.p. injection (ob/ob + vehicle, n = 3; ob/ob + LY426965, n = 5). (G–I) BW (grams; G), fat pad weight 
(percentage of BW; H), and food intake (grams; I) over a period of 24 h in ob/ob mice after 4 wk of daily injection with vehicle or LY426965 compound  
(20 mg/kg/d; ob/ob + vehicle, n = 3; ob/ob + LY426965, n = 5). Data shown are representative of two independent experiments. (J–L) Energy expenditure 
analysis after 4 wk of i.p. daily injection with vehicle or LY426965 compound (20 mg/kg/d) in ob/ob mice (ob/ob + vehicle, n = 3; ob/ob + LY426965,  
n = 3). Volume of oxygen consumption VO2 (milliliter/kilogram/hour; J), heat production (kilocalorie/hour/BW; K), and locomotor activity (XTOT; L) are 
shown. For all experiments: *, P < 0.05 (Student’s t test). Error bars represent SEM.
 50 Leptin-dependent serotonin control of appetite | Yadav et al.
recessive disease called Canavan disease or aspartoacyclase dis-
ease, which is characterized by an increase in appetite. These 
two genes were not known to be affected by leptin signaling 
in  the  brain. We  cannot  exclude  at  the  present  time  that 
CREB regulates the expression of other genes in arcuate neu-
rons that are involved in the control of appetite. In that respect, 
we note that CREB affects the expression of -aminobutyric 
acid receptors or other genes implicated in the regulation of 
appetite (Kalra et al., 1999; Berthoud and Morrison, 2008; 
Dietrich  and  Horvath,  2009).  In  vivo  experiments  are  now 
needed to determine the importance of these two genes in the 
regulation of appetite by serotonin and leptin.
The last point we wanted to explore was whether we 
could take advantage of the wealth of pharmacological infor-
mation surrounding serotonin signaling in the brain to devise 
a strategy to decrease appetite in leptin-deficient mice. This 
would not only be a verification of the importance of sero-
tonin downstream of leptin signaling in the brain but could 
also be viewed as a proof of principle experiment in the on-
going search for additional means to inhibit appetite in mor-
bid obesity. To address this point, we could rely only on a 
small molecule inhibitor of Htr1a, one of the two serotonin 
receptors mediating the orexigenic function of serotonin. As 
a result, any positive results we could obtain would only be 
partial. This being properly acknowledged, our results indicate 
that inhibiting serotonin signaling in the brain decreases   
appetite in leptin-deficient mice. An implication of our results 
is that antagonist of serotonin signaling should not effect on 
the appetite of Pomc1/ and Mc4r/ mice.
Altogether, the experiments presented in this study (a) estab-
lish that inhibition of serotonin synthesis is a mechanism used by 
leptin to regulate appetite in mice, (b) identify additional leptin-
sensitive genes involved in the regulation of appetite, and (c) pro-
vide an initial proof of principle that targeting serotonin in the 
hypothalamus is a viable option to treat hyperphagic diseases.
MATERIALS AND METHODS
Mice generation
To generate mice lacking Htr1a, Htr2b, and Creb in Pomc-expressing neurons, 
flox/+ mice were crossed with Pomc-Cre mice (provided by B. Lowell, Beth 
Israel Deaconess Medical Center, Boston, MA), and their progeny was inter-
crossed to obtain Htr1aPomc
/, Htr2bPomc
/, Htr1a;2bPomc
/, and CrebPomc
/ 
mice. To generate mice lacking Obrb in serotonergic neurons of the brain-
stem after birth, Obrb flox/+ mice were crossed with Tph2-CreERT2; Obrb 
flox/+, and the progeny were injected daily with tamoxifen (1 mg/20 g BW) 
for 5 d at 6 wk of age. All of these mice were in the mixed genetic back-
ground as follows: Htr1aPomc
/, Htr2bPomc
/, and CrebPomc
/ mice (129sv: 
75%; C57BL/6J: 25%), Htr1a;2bPomc
/ (129sv: 87.5%; C57BL/6J: 12.5%), 
and  Tph2-CreERT2;  Obrbf/f  mice  (129sv:  12.5%;  C57BL/6J:  87.5%). WT 
C57BL/6J and ob/ob mice were obtained from The Jackson Laboratory. All 
experiments were conducted according to Columbia University Guidelines 
for the Animal Use and Care of laboratory mice. Mice were bred and main-
tained in our animal facility according to institutional guidelines with proto-
cols approved by the Animal Studies Committee of Columbia University.
Molecular experiments
RNA isolation, cDNA preparation, and real-time PCR analysis were per-
formed  according  to  standard  protocols  using  oligonucleotides  from   
QIAGEN. Genotypes of all mice were determined by PCR.
Histology
Mice were anesthetized and perfused transcardially with ice-cold saline fol-
lowed by 4% paraformaldehyde (PFA). Brains were dissected, fixed in 4% 
PFA overnight at 4°C, cryoprotected by overnight immersion in 20%   
sucrose, embedded in Shandon Cryomatrix (Thermo Fisher Scientific), and 
frozen at 80°C. 20-µm cryostat sections were cut in the coronal plane.   
In situ hybridization and -galactosidase staining were performed according 
to standard procedures in Yadav et al. (2009).
Hypothalamic explants
Brains were dissected in cold artificial cerebrospinal fluid solution and left in 
the same solution for 30 min before being sectioned at 500 µm using a chop-
per at the level of the arcuate nuclei of the hypothalamus (from bregma 
1.22 to 1.70 mm). The resulting slices were incubated in artificial cere-
brospinal fluid for 1 h before treatment.
Immunofluorescence
Immunofluorescence analysis of CREB phosphorylation in hypothalamus 
was performed after 30-min treatment with PBS, 50 µM serotonin, or 50 µM 
serotonin + 50 µM LY426965 on 500-µm brain slices of WT mice. After 
treatment, brain slices were fixed in 4% PFA overnight at 4°C. 20-µm cryo-
stat sections were cut in the coronal plane, blocked in donkey serum, and 
then incubated in p-CREB (S133) rabbit antibody (87G3; Cell Signaling 
Technology) for 24 h at 4°C. Sections were rinsed and incubated with   
a  donkey  anti–rabbit  antibody  (1:1,000;  Cy2;  Jackson  ImmunoResearch 
Laboratories, Inc.).
Microarray analysis
RNA from micro-dissected WT and CrebPomc1
/ mice hypothalami were 
extracted using TRIZOL and analyzed using GeneChip Mouse Genome 
430 2.0 Array (Affymetrix). Data analyses were performed by Precision Bio-
marker using Expression Console software (Affymetrix) and normalized by 
robust multi-array average expression measure. The criteria for increased or 
decreased gene expression were P < 0.05. The heat map is a false color image 
derived from the selected gene expression values with a dendrogram added 
to the left side and to the top. Dendrograms are based on hierarchical clustering. 
Vertical lines indicate the distance between samples (columns) or genes (rows). 
The color red indicates higher relative expression as compared with blue.
Intracerebroventricular leptin infusion or injection
Animals were anesthetized and placed on a stereotaxic instrument (model 
51600; Stoelting). The skin covering the head was then cut, and the calvaria 
were exposed. A hole was drilled upon bregma using a 28-gauge needle.   
A 28-gauge needle cannula (brain infusion kit II; Alzet) was then implanted 
into the hole reaching the third cerebral ventricle according to the following 
coordinates: bregma, 0.3 anteroposterior; 3 mm ventral (0 point bregma). 
Leptin infusions were made according to (Ducy et al., 2000). For acute injec-
tions, PBS or 2 µg leptin was injected with a Hamilton syringe into the third 
cerebral ventricle. Brains were removed (after 4 h for the acute injection), and 
the hypothalamus was carefully dissected.
Experimental regimen for food intake measurement in WT and 
mutant animals
Animals were individually housed in metabolic cages under 12-h light/12-h dark 
conditions with ad libitum feeding. Measurements were performed after a mini-
mum of 4 d of acclimatization to the housing conditions. Control and mutant 
mice were separated into individual cages 1 d before the experiment. Food con-
sumption was determined by weighing the powdered chow every 12 h for 36 h.
Treatment with LY426965
Two  different  experimental  regimens  were  used  to  assess  the  effect  of 
LY426965 on appetite in WT and ob/ob mice.
Experiment I: acute dose response of LY426965 in WT mice. 3-mo-
old  C57BL/6J  inbred  female  mice  were  used  in  these  experiments.   JEM VOL. 208, January 17, 2011 
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